Investors

Amplyx is a privately held company that has successfully completed its Series C financing round, raising a total of $67 million to advance the clinical development of Fosmanogepix and MAU868 for treatment of life-threatening infections. Our largest investors are:

Latest News

Milestones Along Our Journey

Subscribe to News Updates

September 24, 2019/by eallison

Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

September 16, 2019/by eallison

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

September 16, 2019/by eallison

Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

September 9, 2019/by eallison

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

April 12, 2019/by Lauren Fish

Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

February 11, 2019/by eallison

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

Press Release Archive

If you’re a member of the media
and would like to reach Amplyx, please contact:

Heidi Chokeir, Ph.D.
Canale Communications
(619) 849-5377 | heidi@canalecomm.com